University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."
12-Oct-2018 8:05 AM EDT Add to Favorites
A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
28-Sep-2018 11:05 AM EDT Add to Favorites
Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
25-Sep-2018 8:05 AM EDT Add to Favorites
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on...
24-Sep-2018 8:45 AM EDT Add to Favorites
Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.
12-Sep-2018 1:05 PM EDT Add to Favorites
Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
17-Aug-2018 12:15 PM EDT Add to Favorites
University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
8-Aug-2018 11:05 AM EDT Add to Favorites
Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.
30-Jul-2018 10:05 AM EDT Add to Favorites
see all news
27-Jul-2015 11:05 AM EDT
An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges of collaboration between oncologists and pathologists in the context of molecular testing patient tumor samples.
30-May-2014 4:00 PM EDT